Innovent's SYCUME Delivers Phase 3 Win in Inactive Thyroid Eye Disease Thursday, Innovent Biologics (1801.HK) said its Phase 3 RESTORE-3 study met the primary endpoint in patients with inactive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results